The role of bacteria in cancer therapy - Enemies in the past, but allies at present

Infectious Agents and Cancer

Volumn 13, Issue 1, 2018, Pages

  Song, Shiyu ^a   Vuai, Miza S ^a,b   Zhong, Mintao ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b The State Univerisity of Zanzibar   (Tanzania)

Author keywords

Bacteria; Cancer; Detection; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIOCIN; CARBOXYLIC ACID DERIVATIVE; CD4 ANTIGEN; CD8 ANTIGEN; INFLAMMASOME; INTERLEUKIN 2 RECEPTOR ALPHA; ONCOLYTIC VIRUS; PHENAZINE 1,6 DI CARBOXYLIC ACID; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIANGIOGENIC THERAPY; BACTERIAL IMMUNITY; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIUM; BACTERIUM CARRIER; BIOFILM; CANCER RISK; CANCER THERAPY; GENETIC ENGINEERING; HUMAN; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR NECROSIS;

EID: 85043762524     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/s13027-018-0180-y     Document Type: Review

References (78)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30.
2. Chen W, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32.
3. Raguz S, Yague E. Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer. 2008;99(3):387-91.
4. Lax AJ. Opinion: bacterial toxins and cancer - a case to answer? Nat Rev Microbiol. 2005;3(4):343-9.
5. Correa P, et al. Helicobacter pylori and gastric carcinoma. Serum antibody prevalence in populations with contrasting cancer risks. Cancer. 1990;66(12):2569-74.
6. Caygill CP, et al. The association between typhoid carriage, typhoid infection and subsequent cancer at a number of sites. Eur J Cancer Prev. 1995;4(2):187-93.
7. Mesnard B, et al. Immunoproliferative small intestinal disease associated with campylobacter jejuni. Dig Liver Dis. 2012;44(9):799-800.
8. Ferreri AJ, et al. Evidence for an association between chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst. 2004;96(8):586-94.
9. Gupta PK, et al. Mycobacterium tuberculosis H37Rv infected THP-1 cells induce epithelial mesenchymal transition (EMT) in lung adenocarcinoma epithelial cell line (A549). Cell Immunol. 2016;300:33-40.
10. De Spiegeleer B, et al. The quorum sensing peptides PhrG, CSP and EDF promote angiogenesis and invasion of breast cancer cells in vitro. PLoS One. 2015;10(3):e0119471. https://doi.org/10.1371/journal.pone.0119471.
11. Ogrendik M. Oral bacteria in pancreatic cancer: mutagenesis of the p53 tumour suppressor gene. Int J Clin Exp Pathol. 2015;8(9):11835-6.
12. Jacob JA. Study links periodontal disease Bacteria to pancreatic Cancer risk. JAMA. 2016;315(24):2653-4.
13. De Spiegeleer B, et al. The quorum sensing peptides PhrG, CSP and EDF promote angiogenesis and invasion of breast Cancer cells in vitro. PLoS One. 2015;10(3):e0119471.
14. Wynendaele E, et al. Crosstalk between the microbiome and cancer cells by quorum sensing peptides. Peptides. 2015;64(Supplement C):40-8.
15. Leschner S, Weiss S. Salmonella-allies in the fight against cancer. J Mol Med (Berl). 2010;88(8):763-73.
16. Wei MQ, et al. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. Eur J Cancer. 2007;43(3):490-6.
17. Chang J, et al. Pseudomonas aeruginosa preparation plus chemotherapy for advanced non-small-cell lung cancer: a randomized, multicenter, double-blind phase III study. Med Oncol. 2015;32(5):139.
18. Hetz C, et al. Microcin E492, a channel-forming bacteriocin from Klebsiella pneumoniae, induces apoptosis in some human cell lines. Proc Natl Acad Sci U S A. 2002;99(5):2696-701.
19. Pawar V, et al. Murine solid tumours as a novel model to study bacterial biofilm formation in vivo. J Intern Med. 2014;276(2):130-9.
20. Ganai S, et al. In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis. Cancer Gene Ther. 2011;18(7):457-66.
21. Yan L, et al. Photodynamic treatment of tumor with Bacteria expressing KillerRed. PLoS One. 2015;10(7):e0131518.
22. Danino T, et al. Measuring growth and gene expression dynamics of tumor-targeted S. Typhimurium bacteria. J Vis Exp. 2013;77:e50540.
23. Forbes NS. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer. 2010;10(11):785-94.
24. Leschner S, et al. Tumor invasion of Salmonella enterica serovar typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha. PLoS One. 2009;4(8):e6692.
25. Nallar SC, Xu DQ, Kalvakolanu DV. Bacteria and genetically modified bacteria as cancer therapeutics: current advances and challenges. Cytokine. 2017;89:160-72.
26. Coley WB. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med. 1910;3(Surg Sect):1-48.
27. Felgner S, et al. Optimizing Salmonella enterica serovar typhimurium for bacteria-mediated tumor therapy. Gut Microbes. 2016;7(2):171-7.
28. Alexandroff AB, et al. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer. Immunotherapy. 2010;2(4):551-60.
29. Panteli JT, et al. Genetically modified bacteria as a tool to detect microscopic solid tumor masses with triggered release of a recombinant biomarker. Integr Biol (Camb). 2015;7(4):423-34.
30. Danino T, et al. Programmable probiotics for detection of cancer in urine. Sci Transl Med. 2015;7(289):289ra84. https://doi.org/10.1126/scitranslmed.aaa3519.
31. Kucerova P, Cervinkova M. Spontaneous regression of tumour and the role of microbial infection - possibilities for cancer treatment. Anti-Cancer Drugs. 2016;27(4):269-77.
32. Phan TX, et al. Activation of inflammasome by attenuated Salmonella typhimurium in bacteria-mediated cancer therapy. Microbiol Immunol. 2015;59(11):664-75.
33. Netea MG, et al. IL-1beta processing in host defense: beyond the inflammasomes. PLoS Pathog. 2010;6(2):e1000661.
34. Stern C, et al. Induction of CD4(+) and CD8(+) anti-tumor effector T cell responses by bacteria mediated tumor therapy. Int J Cancer. 2015;137(8):2019-28.
35. Erdman SE, et al. CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res. 2003;63(18):6042-50.
36. Westphal K, et al. Containment of tumor-colonizing bacteria by host neutrophils. Cancer Res. 2008;68(8):2952-60.
37. Kaur S, Kaur S. Bacteriocins as potential anticancer agents. Front Pharmacol. 2015;6:272.
38. Chumchalova J, Smarda J. Human tumor cells are selectively inhibited by colicins. Folia Microbiol (Praha). 2003;48(1):111-5.
39. Villarante KI, et al. Purification, characterization and in vitro cytotoxicity of the bacteriocin from Pediococcus acidilactici K2a2-3 against human colon adenocarcinoma (HT29) and human cervical carcinoma (HeLa) cells. World J Microbiol Biotechnol. 2011;27(4):975-80.
40. Tagg JR, Dajani AS, Wannamaker LW. Bacteriocins of gram-positive bacteria. Bacteriol Rev. 1976;40(3):722-56.
41. Paiva AD, et al. Toxicity of bovicin HC5 against mammalian cell lines and the role of cholesterol in bacteriocin activity. Microbiology. 2012;158(Pt 11):2851-8.
42. Joo NE, et al. Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC1. Cancer Med. 2012;1(3):295-305.
43. Hill RP, Farkas-Himsley H. Further studies of the action of a partially purified bacteriocin against a murine fibrosarcoma. Cancer Res. 1991;51(5):1359-65.
44. Mackinnon EM. Chacterizing the pyocin activity of diverse Pseudomonas aeruginosa isolates. In: Department of Molecular Genetics. Toronto: University of Toronto; 2011. p. 65.
45. Ling H, et al. A predicted S-type pyocin shows a bactericidal activity against clinical Pseudomonas aeruginosa isolates through membrane damage. FEBS Lett. 2010;584(15):3354-8.
46. Michel-Briand Y, Baysse C. The pyocins of Pseudomonas aeruginosa. Biochimie. 2002;84(5-6):499-510.
47. Farkas-Himsley H, Cheung R. Bacterial proteinaceous products (bacteriocins) as cytotoxic agents of neoplasia. Cancer Res. 1976;36(10):3561-7.
48. Abdi-Ali A, et al. Cytotoxic effects of pyocin S2 produced by Pseudomonas aeruginosa on the growth of three human cell lines. Can J Microbiol. 2004;50(5):375-81.
49. Podojil M, Gerber NN. Biosynthesis of 1,6-phenazinediol 5,10-dioxide (iodinin). Incorporation of shikimic acid. Biochemistry. 1970;9(23):4616-8.
50. Morales DK, et al. Control of Candida albicans metabolism and biofilm formation by Pseudomonas aeruginosa phenazines. MBio. 2013;4(1):e00526-12.
51. Dasgupta D, et al. Isolation of phenazine 1,6-di-carboxylic acid from Pseudomonas aeruginosa strain HRW.1-S3 and its role in biofilm-mediated crude oil degradation and cytotoxicity against bacterial and cancer cells. Appl Microbiol Biotechnol. 2015;99(20):8653-65.
52. Kinnari TJ. The role of biofilm in chronic laryngitis and in head and neck cancer. Curr Opin Otolaryngol Head Neck Surg. 2015;23(6):448-53.
53. Komor U, et al. Biofilm formation by Pseudomonas aeruginosa in solid murine tumors - a novel model system. Microbes Infect. 2012;14(11):951-8.
54. Huang Q. Comment on "Bacteria form biofilms against cancer metastasis"; 2010. p. 203.
55. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994;64(3):529-64.
56. Johnson CH, et al. Metabolism links bacterial biofilms and colon carcinogenesis. Cell Metab. 2015;21(6):891-7.
57. Weitao T. Bacteria form biofilms against cancer metastasis. Med Hypotheses. 2009;72(4):477-8.
58. Miyake K, Yamamoto S, Iijima S. Blocking adhesion of cancer cells to endothelial cell types by S. Agalactiae type-specific polysaccharides. Cytotechnology. 1996;22(1-3):205-9.
59. Kumeria T, et al. Naturally derived Iron oxide nanowires from Bacteria for magnetically triggered drug release and Cancer hyperthermia in 2D and 3D culture environments: Bacteria biofilm to potent Cancer therapeutic. Biomacromolecules. 2016;17(8):2726-36.
60. Min J-J, et al. Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting Escherichia coli. Mol Imaging Biol. 2008;10(1):54-61.
61. Weibel S, et al. Colonization of experimental murine breast tumours by Escherichia coli K-12 significantly alters the tumour microenvironment. Cell Microbiol. 2008;10(6):1235-48.
62. Min J-J, et al. Quantitative bioluminescence imaging of tumor-targeting bacteria in living animals. Nat Protoc. 2008;3(4):629-36.
63. Yu YA, et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol. 2004;22(3):313-20.
64. Jia LJ, et al. Enhanced therapeutic effect by combination of tumor-targeting Salmonella and endostatin in murine melanoma model. Cancer Biol Ther. 2005;4(8):840-5.
65. Li X, et al. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 2003;10(2):105-11.
66. Xu YF, et al. A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy. Cancer Gene Ther. 2007;14(2):151-7.
67. Fu GF, et al. Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Ther. 2005;12(2):133-40.
68. Niethammer AG, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002;8(12):1369-75.
69. Gardlik R, et al. Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. Gene Ther. 2011;18(5):425-31.
70. Hu B, et al. Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth. Cancer Gene Ther. 2009;16(8):655-63.
71. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658-70.
72. Krzykawski MP. Combined bacterial and viral treatment: a novel anticancer strategy. Cent Eur J Immunol. 2015;40(3):366-72.
73. Kawai K, et al. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci. 2013;104(1):22-7.
74. Cronin M, et al. Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy. Mol Ther. 2014;22(6):1188-97.
75. Park SJ, et al. New paradigm for tumor theranostic methodology using bacteria-based microrobot. Sci Rep. 2013;3:3394.
76. Sharma NN, Mittal RK. Nanorobot movement: Challenges and biologically inspired solutions. Int J Smart Sensing Intell Syst. 2008;1(1):87-109.
77. Gong J, et al. Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat Rev. 2012;38(3):226-34.
78. Park SJ, et al. Effect of chitosan coating on a bacteria-based alginate microrobot. Biotechnol Bioeng. 2015;112(4):769-76.